Implantable cytokine factories designed to deliver immunotherapy directly at the site of disease have taken an important step toward clinical reality. Researchers at Rice University, in collaboration ...
Implantable cytokine factories designed to deliver immunotherapy directly at the site of disease have taken an important step ...
Re-VOLVE: Phase II clinical trial in women with ovarian cancer progressing post-PARP inhibitor with treatment adapted to real-time assessment of evolving genomic resistance. Circulating tumor DNA ...
How reorganizing existing drugs and vaccine components can dramatically alter their potency, selectivity, and even their ...
Infection with HPV16, a high-risk human papillomavirus (HPV), can cause cervical cancer in humans. These infections carry a high risk of morbidity and mortality globally in females. This study aimed ...
Scientists at the University of Pennsylvania have shown for the first time that it’s possible to detect dormant cancer cells in breast cancer survivors and eliminate them with repurposed drugs, ...
Engineered nanoparticles can improve cancer immunotherapy by delivering drugs, antigens, and genetic payloads with greater ...
Implantable cytokine factories designed to deliver immunotherapy directly at the site of disease have taken an important step ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results